Functional characterization of D9, a novel deazaneplanocin a (DZNep) analog, in targeting acute myeloid leukemia (AML)

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Jiang, Xia ^a   Lim, Cheryl Zi Hui ^a   Li, Zhimei ^a   Lee, Puay Leng ^a   Yatim, Siti Maryam J M ^a   Guan, Peiyong ^a   Li, Juntao ^a   Zhou, Jianbiao ^b   Pan, Jingxuan ^c   Chng, Wee Joo ^b,d,e   Chai, Christina L L ^f,g   Yu, Qiang ^a,h,i  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SUN YAT SEN UNIVERSITY   (China)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^e Dept Medicine Endocrinol Diabet   (Singapore)

^f INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES   (Singapore)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h JINAN UNIVERSITY   (China)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; ADENOSINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG STRUCTURE; EC50; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; GENETIC EPIGENESIS; HL-60 CELL LINE; LEUKEMIA, MYELOID, ACUTE; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY;

ADENOSINE; ANIMALS; DRUG DELIVERY SYSTEMS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928673723     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122983     Document Type: Article

References (46)

1. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005 Aug 15; 106(4):1154-63. PMID: 15870183
2. Stone RM. Targeted agents in AML: much more to do. Best Pract Res Clin Haematol. 2007 Mar; 20 (1):39-48. PMID: 17336253
3. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973 Nov-Dec; 57 (4):485-8. PMID: 4586956
4. Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:43-50. doi: 10.1182/asheducation-2011.1.43 PMID: 22160011
5. Ninomiya M, Abe A, Katsumi A, Xu J, Ito M, Arai F, et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia. 2007 Jan; 21(1):136-42. PMID: 17039228
6. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007 Nov; 25(11):1315-21. PMID: 17952057
7. Roboz GJ, Guzman M. Acute myeloid leukemia stem cells: seek and destroy. Expert Rev Hematol. 2009 Dec; 2(6):663-72. doi: 10.1586/ehm.09.53 PMID: 21082958
8. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011 Jan 18; 19(1):138-52. doi: 10.1016/j.ccr.2010.12.012 PMID: 21251617
9. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 Nov; 8 (11):890-6. doi: 10.1038/nchembio.1084 PMID: 23023262
10. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012 Dec 6; 492 (7427):108-12. doi: 10.1038/nature11606 PMID: 23051747
11. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007 Nov; 7(11):823-33. PMID: 17957188
12. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011 Jul 12; 20(1):66-78. doi: 10.1016/j.ccr.2011.06.010 PMID: 21741597
13. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011 Jul 12; 20(1):53-65. doi: 10.1016/j.ccr.2011.06.009 PMID: 21741596
14. Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007 Feb 9; 25(3):473-81. PMID: 17289593
15. Liu F, Chen X, Allali-Hassani A, Quinn AM, Wigle TJ, Wasney GA, et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalk-oxyquinazolines. J Med Chem. 2010 Aug 12; 53(15):5844-57. doi: 10.1021/jm100478y PMID: 20614940
16. Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol. 2011 Aug; 7(8):566-74. doi: 10.1038/nchembio.599 PMID: 21743462
17. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007 May 1; 21(9):1050-63. PMID: 17437993
18. Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P, et al. BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res. 2009; 11(4):R63. doi: 10.1186/bcr2354 PMID: 19709408
19. Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE, et al. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer. 2011; 10:40. doi: 10.1186/1476-4598-10-40 PMID: 21501485
20. Hayden A, Johnson PW, Packham G, Crabb SJ. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Treat. 2011 May; 127(1):109-19. doi: 10.1007/s10549-010-0982-0 PMID: 20556507
21. Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012 Nov; 78(2):138-43. doi: 10.1016/j.lungcan.2012.08.003 PMID: 22925699
22. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009 Dec 15; 69(24):9211-8. doi: 10.1158/0008-5472.CAN-09-1622 PMID: 19934320
23. Jiang X, Tan J, Li J, Kivimae S, Yang X, Zhuang L, et al. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 2008 Jun; 13(6):529-41. doi: 10.1016/j.ccr.2008.04.019 PMID: 18538736
24. Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011 Sep 8; 118(10):2830-9. doi: 10.1182/blood-2010-07-294827 PMID: 21734239
25. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009 Sep 24; 114(13):2733-43. doi: 10.1182/blood-2009-03-213496 PMID: 19638619
26. Tam EK, Nguyen TM, Lim CZ, Lee PL, Li Z, Jiang X, et al. 3-Deazaneplanocin A and neplanocin A analogues and their effects on apoptotic cell death. ChemMedChem. 2015 Jan; 10(1):173-82. doi: 10.1002/cmdc.201402315 PMID: 25319940
27. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009 Nov 10; 27(32):5410-7. doi: 10.1200/JCO.2008.21.6150 PMID: 19826128
28. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008 Jul 1; 123(1):8-13. doi: 10.1002/ijc.23607 PMID: 18425818
29. Milella M, Precupanu CM, Gregorj C, Ricciardi MR, Petrucci MT, Kornblau SM, et al. Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des. 2005; 11(21):2779-95. PMID: 16101455
30. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, et al. Functional proteomic profiling of AML predicts response and survival. Blood. 2009 Jan 1; 113(1):154-64. doi: 10.1182/blood-2007-10-119438 PMID: 18840713
31. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol. 2005 Mar; 5(3):189-200. PMID: 15719025
32. Hubner A, Barrett T, Flavell RA, Davis RJ. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell. 2008 May 23; 30(4):415-25. doi: 10.1016/j.molcel.2008.03.025 PMID: 18498746
33. Bouillet P, Zhang LC, Huang DC, Webb GC, Bottema CD, Shore P, et al. Gene structure alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim. Mamm Genome. 2001 Feb; 12(2):163-8. PMID: 11210187
34. Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res. 2005 Dec 1; 65(23):11018-25. PMID: 16322251
35. Zhao P, Meng Q, Liu LZ, You YP, Liu N, Jiang BH. Regulation of survivin by PI3K/Akt/p70S6K1 pathway. Biochem Biophys Res Commun. 2010 Apr 30; 395(2):219-24. doi: 10.1016/j.bbrc.2010.03.165 PMID: 20361940
36. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science. 2013 Mar 29; 339(6127):1567-70. doi: 10.1126/science.1230184 PMID: 23539597
37. Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev. 2012 Feb 15; 26(4):344-9. doi: 10.1101/gad.184341.111 PMID: 22345515
38. Hu X, Moscinski LC, Hill BJ, Chen Q, Wu J, Fisher AB, et al. Characterization of a unique factor-independent variant derived from human factor-dependent TF-1 cells: a transformed event. Leuk Res. 1998 Sep; 22(9):817-26. PMID: 9716013
39. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012 Dec 26; 109(52):21360-5. doi: 10.1073/pnas.1210371110 PMID: 23236167
40. Wee ZN, Li Z, Lee PL, Lee ST, Lim YP, Yu Q. EZH2-Mediated Inactivation of IFN-gamma-JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate Cancer. Cell Rep. 2014 Jun 17.
41. Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 2004 Apr 15; 64(8):2817-24. PMID: 15087398
42. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008 May 16; 133(4):704-15. doi: 10.1016/j.cell.2008.03.027 PMID: 18485877
43. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets. 2010 May; 10(3):268-78. PMID: 20370691
44. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 2011 Jan; 8(1):27-33. doi: 10.1038/nrgastro.2010.188 PMID: 21102532
45. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999 Mar 1; 93(5):1658-67. PMID: 10029595
46. Damiano JS, Dalton WS. Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma. 2000 Jun; 38(1-2):71-81. PMID: 10953981